在AML中选择性EV蛋白排序和途径扰乱在协同FLT3和刺途径抑制后的AML中
Constantin Blöchl1, Gabriele Blümel1, Martin Wolf2,3
1Department of Biosciences and Medical Biology, University of Salzburg, Salzburg, Austria.
Journal of extracellular vesicles
|September 23, 2025
概括
克雷诺拉尼布和HPI-1的联合治疗在急性髓性白血病 (AML) 细胞中显示出协同效应. 克雷诺拉尼布通过改变细胞外囊泡蛋白质运输来干扰白血病利基形成.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 细胞生物学 细胞生物学
背景情况:
- 急性髓性白血病 (AML) 是一种血液癌症,结果不佳,通常涉及FLT3突变.
- 来自AML细胞的细胞外囊泡 (EV) 促进支持性的微环境和化学抵抗.
- 刺信号和GLI表达与AML病变发生有关.
研究的目的:
- 为了研究FLT3抑制剂Crenolanib和黑途径抑制剂HPI-1在AML中的协同作用.
- 在联合抑制后分析AML细胞和EVs中的蛋白质变化.
- 了解Crenolanib如何影响EV货物和白血病利基形成.
主要方法:
- 针对AML细胞系 (MOLM-14, MV4-11) 和患者衍生的EVs的比较蛋白质组学.
- 用克雷诺拉尼布 (FLT3 抑制剂) 和HPI-1 (刺线路抑制剂) 治疗.
- 对细胞和EV蛋白质组的分析,以确定途径的改变.
主要成果:
- 联合Crenolanib和HPI-1治疗在AML细胞系中显示出协同效应.
- 蛋白质组分析显示了细胞和EV蛋白质组的显著变化.
- 克雷诺拉尼布选择性地抑制了核糖体蛋白质 (例如RPS26,RPL27A) 和ErbB通路蛋白质 (例如GAB1,GRB2,SHC1) 到EV的传输.
- 与健康捐赠者相比,来自AML患者的EV显示出明显的蛋白质组概况.
结论:
- 联合抑制FLT3和刺信号提供了AML潜在的治疗策略.
- 克雷诺拉尼布通过调节EV成分来干扰白血病利基形成.
- 核糖体和ErbB信号通路是通过EV调制进行AML治疗的关键标.
相关概念视频
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Interactions Between Signaling Pathways
7.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.2K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Adaptive Mechanisms in Cancer Cells
7.0K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.0K


